{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:03:42Z","timestamp":1791925422708,"version":"4.3.4"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T00:00:00Z","timestamp":1616112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T00:00:00Z","timestamp":1616112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001804","name":"Canada Research Chairs","doi-asserted-by":"publisher","award":["17-0126-AWA"],"award-info":[{"award-number":["17-0126-AWA"]}],"id":[{"id":"10.13039\/501100001804","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001804","name":"Canada Research Chairs","doi-asserted-by":"publisher","award":["17-0245-SUB"],"award-info":[{"award-number":["17-0245-SUB"]}],"id":[{"id":"10.13039\/501100001804","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s11606-021-06642-7","type":"journal-article","created":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T20:10:31Z","timestamp":1616184631000},"page":"2414-2426","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Comparative Efficacy and Safety of Ultra-Long-Acting, Long-Acting, Intermediate-Acting, and Biosimilar Insulins for Type 1 Diabetes Mellitus: a Systematic Review and Network Meta-Analysis"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4114-8971","authenticated-orcid":false,"given":"Andrea C.","family":"Tricco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huda M.","family":"Ashoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesmin","family":"Antony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Bouck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myanca","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ba\u2019","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Nincic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazia","family":"Darvesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Yazdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Ghassemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Ivory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Areti Angeliki","family":"Veroniki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine H.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Moja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon E.","family":"Straus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,19]]},"reference":[{"key":"6642_CR1","doi-asserted-by":"crossref","unstructured":"American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes\u20142018. Diabetes Care. 2018;41(Supplement 1):S13-S27.","DOI":"10.2337\/dc18-S002"},{"key":"6642_CR2","doi-asserted-by":"publisher","first-page":"S80","DOI":"10.1016\/j.jcjd.2017.10.012","volume":"42","author":"M Angela McGibbon","year":"2018","unstructured":"Angela McGibbon M, Lenley Adams M, Karen Ingersoll R, Barna Tugwell M. Glycemic management in adults with type 1 diabetes. Can J Diabetes 2018;42:S80-S7.","journal-title":"Can J Diabetes"},{"issue":"3","key":"6642_CR3","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.diabres.2011.09.001","volume":"94","author":"AC Sanches","year":"2011","unstructured":"Sanches AC, Correr CJ, Venson R, Pontarolo R. Revisiting the efficacy of long-acting insulin analogues on adults with type 1 diabetes using mixed-treatment comparisons. Diabetes Res Clin Pract 2011;94(3):333-9.","journal-title":"Diabetes Res Clin Pract"},{"key":"6642_CR4","doi-asserted-by":"crossref","unstructured":"Vardi M, Jacobson E, Nini A, Bitterman H. Intermediate acting versus long acting insulin for type 1 diabetes mellitus. Cochrane Database Syst Rev. 2008(3):Cd006297.","DOI":"10.1002\/14651858.CD006297.pub2"},{"issue":"11","key":"6642_CR5","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1111\/dme.12243","volume":"30","author":"BW Bode","year":"2013","unstructured":"Bode BW, Buse JB, Fisher M, et al. Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN((R)) Basal-Bolus Type 1): 2-year results of a randomized clinical trial. Diabet Med 2013;30(11):1293-7.","journal-title":"Diabet Med"},{"issue":"1","key":"6642_CR6","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1080\/20573316.2017.1340246","volume":"14","author":"J James","year":"2017","unstructured":"James J, Pollom RK, Hadjiyianni I, Buchholz G, Reed BL. Biosimilar insulins: What do you need to know? Int Diabetes Nursing 2017;14(1):32-5.","journal-title":"Int Diabetes Nursing"},{"issue":"4","key":"6642_CR7","doi-asserted-by":"publisher","first-page":"e0195012","DOI":"10.1371\/journal.pone.0195012","volume":"13","author":"C Tieu","year":"2018","unstructured":"Tieu C, Lucas EJ, DePaola M, Rosman L, Alexander GC. Efficacy and safety of biosimilar insulins compared to their reference products: A systematic review. PLoS One 2018;13(4):e0195012.","journal-title":"PLoS One"},{"issue":"7","key":"6642_CR8","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1111\/dom.13291","volume":"20","author":"T Yamada","year":"2018","unstructured":"Yamada T, Kamata R, Ishinohachi K, et al. Biosimilar vs originator insulins: Systematic review and meta-analysis. Diabetes Obes Metab 2018;20(7):1787-92.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"6642_CR9","doi-asserted-by":"publisher","first-page":"195","DOI":"10.4158\/EP161728.RA","volume":"24","author":"R Dolinar","year":"2018","unstructured":"Dolinar R, Lavernia F, Edelman S. A Guide to follow-on biologics and biosimilars with a focus on insulin. Endocr Pract 2018;24(2):195-204.","journal-title":"Endocr Pract"},{"issue":"1","key":"6642_CR10","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1177\/1932296813516958","volume":"8","author":"L Heinemann","year":"2014","unstructured":"Heinemann L, Hompesch M. Biosimilar Insulins: Basic Considerations. J Diabetes Sci Technol 2014;8(1):6-13.","journal-title":"J Diabetes Sci Technol"},{"issue":"1","key":"6642_CR11","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1177\/8755122518802268","volume":"35","author":"J White","year":"2019","unstructured":"White J, Goldman J. Biosimilar and follow-on insulin: The ins, outs, and interchangeability. J Pharm Technol 2019;35(1):25-35.","journal-title":"J Pharm Technol"},{"key":"6642_CR12","first-page":"349","volume":"g5459","author":"AC Tricco","year":"2014","unstructured":"Tricco AC, Ashoor HM, Antony J, et al. Safety, effectiveness, and cost effectiveness of long acting versus intermediate acting insulin for patients with type 1 diabetes: systematic review and network meta-analysis. BMJ. 2014;349:g5459.","journal-title":"BMJ."},{"key":"6642_CR13","unstructured":"Word Health Organization. Pilot Procedure for Prequalification of Human Insulin. 2020. [Available from: https:\/\/www.who.int\/medicines\/regulation\/prequalification\/pq_human_insulin\/en\/]."},{"key":"6642_CR14","doi-asserted-by":"crossref","unstructured":"Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;350:g7647.","DOI":"10.1136\/bmj.g7647"},{"key":"6642_CR15","unstructured":"Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from https:\/\/www.handbook.cochrane.org."},{"issue":"11","key":"6642_CR16","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 2015;162(11):777-84.","journal-title":"Ann Intern Med"},{"issue":"2","key":"6642_CR17","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.jval.2014.01.004","volume":"17","author":"JP Jansen","year":"2014","unstructured":"Jansen JP, Trikalinos T, Cappelleri JC, et al. Indirect treatment comparison\/network meta-analysis study questionnaire to assess relevance and credibility to inform health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report. Value Health 2014;17(2):157-73.","journal-title":"Value Health"},{"issue":"9","key":"6642_CR18","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/j.jclinepi.2008.10.012","volume":"62","author":"M Sampson","year":"2009","unstructured":"Sampson M, McGowan J, Cogo E, Grimshaw J, Moher D, Lefebvre C. An evidence-based practice guideline for the peer review of electronic search strategies. J Clin Epidemiol 2009;62(9):944-52.","journal-title":"J Clin Epidemiol"},{"key":"6642_CR19","unstructured":"Grey matters: a practical tool for searching health-related grey literature. Ottawa: CADTH; 2018. [Available from:\u00a0https:\/\/www.cadth.ca\/resources\/finding-evidence]."},{"key":"6642_CR20","unstructured":"Synthesi.SR. Toronto, Canada: Knowledge Translation Program, St. Michael's Hospital; 2012."},{"issue":"3","key":"6642_CR21","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1002\/jrsm.1240","volume":"8","author":"D Jackson","year":"2017","unstructured":"Jackson D, Turner R. Power analysis for random-effects meta-analysis. Res Synth Methods 2017;8(3):290-302.","journal-title":"Res Synth Methods"},{"issue":"8","key":"6642_CR22","doi-asserted-by":"publisher","first-page":"e0133023","DOI":"10.1371\/journal.pone.0133023","volume":"10","author":"T Li","year":"2015","unstructured":"Li T, Yu T, Hawkins BS, Dickersin K. Design, Analysis, and Reporting of Crossover Trials for Inclusion in a Meta-Analysis. PLoS One 2015;10(8):e0133023.","journal-title":"PLoS One"},{"key":"6642_CR23","unstructured":"StataCorp. Stata Statistical Software: Release 15. College Station, TX: StataCorp LLC; 2017."},{"issue":"11","key":"6642_CR24","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21(11):1539-58.","journal-title":"Stat Med"},{"issue":"5","key":"6642_CR25","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1177\/0272989X12458724","volume":"33","author":"S Dias","year":"2013","unstructured":"Dias S, Sutton AJ, Ades AE, Welton NJ. Evidence Synthesis for Decision Making 2:A Generalized Linear Modeling Framework for Pairwise and Network Meta-analysis of Randomized Controlled Trials. Med Decis Mak 2013;33(5):607-17.","journal-title":"Med Decis Mak"},{"key":"6642_CR26","doi-asserted-by":"crossref","unstructured":"Dias S, Ades AE, Welton NJ, Jansen JP, Sutton AJ. Network Meta-Analysis for Decision-Making: Wiley; 2018.","DOI":"10.1002\/9781118951651"},{"key":"6642_CR27","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jclinepi.2016.11.002","volume":"82","author":"M Petropoulou","year":"2017","unstructured":"Petropoulou M, Nikolakopoulou A, Veroniki AA, et al. Bibliographic study showed improving statistical methodology of network meta-analyses published between 1999 and 2015. J Clin Epidemiol 2017;82:20-8.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"6642_CR28","doi-asserted-by":"publisher","first-page":"e86754","DOI":"10.1371\/journal.pone.0086754","volume":"9","author":"A Nikolakopoulou","year":"2014","unstructured":"Nikolakopoulou A, Chaimani A, Veroniki AA, Vasiliadis HS, Schmid CH, Salanti G. Characteristics of Networks of Interventions: A Description of a Database of 186 Published Networks. PLoS One 2014;9(1):e86754.","journal-title":"PLoS One"},{"issue":"2","key":"6642_CR29","doi-asserted-by":"publisher","first-page":"130","DOI":"10.7326\/0003-4819-159-2-201307160-00008","volume":"159","author":"A Cipriani","year":"2013","unstructured":"Cipriani A, Higgins JP, Geddes JR, Salanti G. Conceptual and technical challenges in network meta-analysis. Ann Intern Med 2013;159(2):130-7.","journal-title":"Ann Intern Med"},{"issue":"2","key":"6642_CR30","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/jrsm.1037","volume":"3","author":"G Salanti","year":"2012","unstructured":"Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res Synth Methods 2012;3(2):80-97.","journal-title":"Res Synth Methods"},{"key":"6642_CR31","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/1741-7015-11-159","volume":"11","author":"JP Jansen","year":"2013","unstructured":"Jansen JP, Naci H. Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers. BMC Med 2013;11:159.","journal-title":"BMC Med"},{"issue":"2","key":"6642_CR32","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/jrsm.1044","volume":"3","author":"JP Higgins","year":"2012","unstructured":"Higgins JP, Jackson D, Barrett JK, Lu G, Ades AE, White IR. Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods 2012;3(2):98-110.","journal-title":"Res Synth Methods"},{"issue":"2","key":"6642_CR33","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/jrsm.1045","volume":"3","author":"IR White","year":"2012","unstructured":"White IR, Barrett JK, Jackson D, Higgins JP. Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression. Res Synth Methods 2012;3(2):111-25.","journal-title":"Res Synth Methods"},{"issue":"1","key":"6642_CR34","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1093\/ije\/dys222","volume":"42","author":"AA Veroniki","year":"2013","unstructured":"Veroniki AA, Vasiliadis HS, Higgins JP, Salanti G. Evaluation of inconsistency in networks of interventions. Int J Epidemiol 2013;42(1):332-45.","journal-title":"Int J Epidemiol"},{"issue":"10","key":"6642_CR35","doi-asserted-by":"publisher","first-page":"e76654","DOI":"10.1371\/journal.pone.0076654","volume":"8","author":"A Chaimani","year":"2013","unstructured":"Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G. Graphical tools for network meta-analysis in STATA. PLoS One 2013;8(10):e76654.","journal-title":"PLoS One"},{"issue":"2","key":"6642_CR36","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1177\/1536867X1101100206","volume":"11","author":"IR White","year":"2011","unstructured":"White IR. Multivariate random-effects meta-regression: updates to mvmeta. Stata J 2011;11(2):255-70.","journal-title":"Stata J"},{"issue":"4","key":"6642_CR37","doi-asserted-by":"publisher","first-page":"247","DOI":"10.2298\/VSP0704247P","volume":"64","author":"M Pesic","year":"2007","unstructured":"Pesic M, Zivic S, Radenkovic S, Velojic M, Dimic D, Antic S. Comparison between basal insulin glargine and NPH insulin in patients with diabetes type 1 on conventional intensive insulin therapy. Vojnosanit Pregl 2007;64(4):247-52.","journal-title":"Vojnosanit Pregl"},{"key":"6642_CR38","doi-asserted-by":"crossref","unstructured":"Ludemann J, Milek K, Wilhelm B, Segner A, Jaeckel E.\u00a0Daytime flexible application of Insulin degludec in patients with type 1 diabetes or type 2 diabetes. MMW Fortschr Med. 2014;156 Suppl 3:89-97.","DOI":"10.1007\/s15006-014-3481-0"},{"issue":"4","key":"6642_CR39","doi-asserted-by":"publisher","first-page":"130","DOI":"10.14341\/DM7694","volume":"18","author":"MV Shestakova","year":"2015","unstructured":"Shestakova MV, Antciferov MV, Mayorov AY, et al. Insulin degludec: a new basal insulin analogue with an ultra-long duration of action. Safety and efficacy in Russian patients with diabetes. Diabetes Mellitus 2015;18(4):130-41.","journal-title":"Diabetes Mellitus"},{"issue":"4","key":"6642_CR40","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.endonu.2010.02.001","volume":"57","author":"R Segovia Portoles","year":"2010","unstructured":"Segovia Portoles R, Ferrer-Garcia JC, Merino-Torres JF, Penalba MT, Albalat Galera R, Pinon-Selles F. Optimal timing of insulin detemir injection in patients with type 1 diabetes and poor metabolic control. Endocrinol Nutr 2010;57(4):140-6.","journal-title":"Endocrinol Nutr"},{"key":"6642_CR41","unstructured":"Hinneburg I. Insulindegludec, a new option for basal insulin needs. Med Monatsschr Pharm 2012:265-6."},{"issue":"9","key":"6642_CR42","first-page":"649","volume":"50","author":"M Kobayashi","year":"2007","unstructured":"Kobayashi M, Iwamoto Y, Kaku K, Kawamori R, Tajima N. 48-week Randomized Multicenter Open-label Parallel Group Phase 3 Trial to Compare Insulin Detemir and NPH Insulin Efficacy and Safety in Subjects with Insulin Requiring Diabetes Mellitus in a Basal-bolus Regimen. J Jpn Diabetes Soc 2007;50(9):649-63.","journal-title":"J Jpn Diabetes Soc"},{"key":"6642_CR43","unstructured":"Philippo H. A 26-week, Multi-centre, Open-labelled, Randomised, Parallel Efficacy and Safety Comparison of Insulin Detemir and NPH Insulin in Adult Patients with Type 1 Diabetes Mellitus on a Basal-Bolus Regimen Novo Nordisk. 2007. [Available from: http:\/\/www.clinicaltrials.gov\/ct2\/show\/study\/NCT00595374]."},{"key":"6642_CR44","unstructured":"Vaughan K. An Open-Label, Randomized, Multi-center, Parallel-Group Clinical Trial Comparing the Efficacy and Safety of Mylan's Insulin Glargine with Lantus in Type 1 Diabetes Mellitus Patients. 2017. [Available from: https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2014-000747-32\/results]."},{"issue":"6","key":"6642_CR45","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.2337\/diabetes.53.6.1614","volume":"53","author":"T Heise","year":"2004","unstructured":"Heise T, Nosek L, Ronn BB, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004;53(6):1614-20.","journal-title":"Diabetes."},{"issue":"5","key":"6642_CR46","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/S0149-2918(04)90072-0","volume":"26","author":"D Russell-Jones","year":"2004","unstructured":"Russell-Jones D, Simpson R, Hylleberg B, Draeger E, Bolinder J. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen. Clin Ther 2004;26(5):724-36.","journal-title":"Clin Ther"},{"issue":"3","key":"6642_CR47","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1210\/jc.2012-3249","volume":"98","author":"C Mathieu","year":"2013","unstructured":"Mathieu C, Hollander P, Miranda-Palma B, et al. Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension. J Clin Endocrinol Metab 2013;98(3):1154-62.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9825","key":"6642_CR48","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/S0140-6736(12)60204-9","volume":"379","author":"S Heller","year":"2012","unstructured":"Heller S, Buse J, Fisher M, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012;379(9825):1489-97.","journal-title":"Lancet."},{"issue":"8","key":"6642_CR49","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1517\/17425255.2015.1058779","volume":"11","author":"T Heise","year":"2015","unstructured":"Heise T, Hovelmann U, Nosek L, Hermanski L, Bottcher SG, Haahr H. Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine. Expert Opin Drug Metab Toxicol 2015;11(8):1193-201.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"1","key":"6642_CR50","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s00125-013-3056-0","volume":"57","author":"G Koehler","year":"2014","unstructured":"Koehler G, Heller S, Korsatko S, et al. Insulin degludec is not associated with a delayed or diminished response to hypoglycaemia compared with insulin glargine in type 1 diabetes: a double-blind randomised crossover study. Diabetologia 2014;57(1):40-9.","journal-title":"Diabetologia."},{"issue":"4","key":"6642_CR51","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s13300-017-0269-0","volume":"8","author":"R Iga","year":"2017","unstructured":"Iga R, Uchino H, Kanazawa K, et al. Glycemic Variability in Type 1 Diabetes Compared with Degludec and Glargine on the Morning Injection: An Open-label Randomized Controlled Trial. Diabetes Ther 2017;8(4):783-92.","journal-title":"Diabetes Ther"},{"issue":"3","key":"6642_CR52","doi-asserted-by":"publisher","first-page":"661","DOI":"10.2337\/dc10-1925","volume":"34","author":"KI Birkeland","year":"2011","unstructured":"Birkeland KI, Home PD, Wendisch U, et al. Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. Diabetes Care 2011;34(3):661-5.","journal-title":"Diabetes Care"},{"issue":"2","key":"6642_CR53","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/dom.12588","volume":"18","author":"T Heise","year":"2016","unstructured":"Heise T, Bain SC, Bracken RM, et al. Similar risk of exercise-related hypoglycaemia for insulin degludec to that for insulin glargine in patients with type 1 diabetes: a randomized cross-over trial. Diabetes Obes Metab 2016;18(2):196-9.","journal-title":"Diabetes Obes Metab"},{"key":"6642_CR54","doi-asserted-by":"crossref","unstructured":"Lane W, Bailey TS, Gerety G, et al. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial. JAMA 2017;318(1):33-44.","DOI":"10.1001\/jama.2017.7115"},{"issue":"7","key":"6642_CR55","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1111\/dom.12938","volume":"19","author":"T Heise","year":"2017","unstructured":"Heise T, Norskov M, Nosek L, Kaplan K, Famulla S, Haahr HL. Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U\/mL in type 1 diabetes. Diabetes Obes Metab 2017;19(7):1032-9.","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"6642_CR56","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s40261-013-0096-7","volume":"33","author":"S Korsatko","year":"2013","unstructured":"Korsatko S, Deller S, Koehler G, et al. A comparison of the steady-state pharmacokinetic and pharmacodynamic profiles of 100 and 200 U\/mL formulations of ultra-long-acting insulin degludec. Clin Drug Investig 2013;33(7):515-21.","journal-title":"Clin Drug Investig"},{"issue":"9","key":"6642_CR57","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/j.1463-1326.2012.01627.x","volume":"14","author":"T Heise","year":"2012","unstructured":"Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr H. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab 2012;14(9):859-64.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"6642_CR58","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.diabet.2017.10.001","volume":"44","author":"TS Bailey","year":"2018","unstructured":"Bailey TS, Pettus J, Roussel R, et al. Morning administration of 0.4U\/kg\/day insulin glargine 300U\/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100U\/mL in type 1 diabetes. Diabetes Metab 2018;44(1):15-21.","journal-title":"Diabetes Metab"},{"issue":"21","key":"6642_CR59","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1161\/CIRCULATIONAHA.115.008722","volume":"133","author":"VJ Wirtz","year":"2016","unstructured":"Wirtz VJ, Kaplan WA, Kwan GF, Laing RO. Access to Medications for Cardiovascular Diseases in Low- and Middle-Income Countries. Circulation 2016;133(21):2076-85.","journal-title":"Circulation."},{"key":"6642_CR60","unstructured":"World Health Organization. NCD Global Monitoring Framework. 2019. [Available from: https:\/\/www.who.int\/nmh\/global_monitoring_framework\/en\/]."}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-021-06642-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11606-021-06642-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-021-06642-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,19]],"date-time":"2022-03-19T01:26:20Z","timestamp":1647653180000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11606-021-06642-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,19]]},"references-count":60,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["6642"],"URL":"https:\/\/doi.org\/10.1007\/s11606-021-06642-7","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,19]]},"assertion":[{"value":"24 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}